Sometimes the key to making a breakthrough in research, in any field, is to look at the problem differently than anybody has ...

Fear of change is a key limiting factor that is slowing the adoption and value of AI across life sciences. It doesn't have to ...

Cuts to federal research funding at universities and research organizations are pushing academic scientists into life ...

BIO was as busy as ever in Boston this year. With more to come soon, here are a few initial thoughts on three events I ...

New IRS requirements for R&D tax credits are coming into effect for tax year 2025. Life sciences companies should prepare for ...

Proper legal structuring is essential when it comes to transferring Chinese biotech intellectual property and clinical assets ...

Experts at PA Consulting offer case studies and advice for using generative AI to improve biopharma manufacturing, mitigate ...

The European Union (EU) is actively courting biotech for economic growth and has launched several initiatives to attract ...

A revolution is coming in the U.S. generics marketplace, one that players in the space ignore at their peril. This revolution has the potential to transform savvy organizations into engines of growth, ...

In this series, we will monitor emerging policies and priorities from the new Trump administration and its agencies that are expected to have particular effects on healthcare and life science-related ...

By Ben Comer, Chief Editor, Life Science Leader. Adam Mendelsohn, Ph.D. Overcoming adherence and tolerability issues in obesity and diabetes treatment. Snapshot. Vivani’s subdermal implant NanoPortal ...

In the realm of pharmaceutical patent litigation, settlement agreements between branded and generic pharmaceutical companies are frequently used to resolve disputes before, during, and after trials in ...